Core Viewpoint - The article highlights the significant increase in the stock price of Heptagon Pharmaceuticals, driven by substantial investment from GIC, a Singapore sovereign wealth fund, which has raised interest in the innovative drug sector in Hong Kong [2][3]. Group 1: Stock Performance - Heptagon Pharmaceuticals' stock rose by 9.16% on September 3, 2023, with a year-to-date increase of approximately 712% [3]. - The stock closed at 16.08 HKD, with a trading volume of 13.68 million shares and a market capitalization of approximately 13.29 billion HKD [4]. Group 2: GIC Investment - On August 29, 2023, GIC purchased 40.22 million shares of Heptagon Pharmaceuticals at an average price of 12.7133 HKD per share, totaling around 511 million HKD [6]. - Following this investment, GIC holds a 6.37% stake, making it the second-largest institutional shareholder, while AstraZeneca remains the largest with a 9.03% stake [8]. Group 3: AstraZeneca's Involvement - AstraZeneca invested in Heptagon Pharmaceuticals at a 40% premium, becoming the largest institutional shareholder with approximately 76.27 million shares [7][10]. - The investment agreement allows AstraZeneca to have licensing options on two preclinical immunology projects developed by Heptagon Pharmaceuticals [12]. Group 4: Financial Performance - Heptagon Pharmaceuticals reported a total revenue of approximately 725 million RMB (about 101 million USD) for the first half of 2025, marking a 327% year-on-year increase [12]. - The net profit for the same period was approximately 523 million RMB (about 73 million USD), reflecting a 51-fold increase compared to the previous year [12]. - The company's cash reserves reached approximately 2.29 billion RMB (about 320 million USD), a 92% increase from the end of the previous year [12].
主权基金增持，知名医药公司大涨